1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,250 | 8,340 | 22:25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Devyser Q4 2025 slides: Revenue growth and positive EBIT mark turnaround year | 1 | Investing.com | ||
| 12.02. | Devyser: Umsatzwachstum und positives EBIT markieren die Trendwende im Geschäftsjahr 2025 | 1 | Investing.com Deutsch | ||
| 12.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2025 | 135 | GlobeNewswire (Europe) | "The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1 million (-62.3)... ► Artikel lesen | |
| 11.02. | Devyser Diagnostics AB: Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market | 766 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products | 513 | GlobeNewswire (Europe) | Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products... ► Artikel lesen | |
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 134 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 150 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen | |
| 28.11.25 | Devyser Diagnostics AB: Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test | 792 | GlobeNewswire (Europe) | Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's PrenatalDetect RHD test (CPT 0536U) at $192. The non-invasive... ► Artikel lesen | |
| 25.11.25 | Devyser Diagnostics AB: Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study | 329 | GlobeNewswire (Europe) | Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution... ► Artikel lesen | |
| 05.11.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2025 | 161 | GlobeNewswire (Europe) | "I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major companies in... ► Artikel lesen | |
| 04.11.25 | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 292 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09.25 | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 159 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 22.07.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 229 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06.25 | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 240 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 467 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04.25 | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 338 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 83,94 | +1,56 % | Medtronic Launches MiniMed Go Smart MDI System In Europe | WASHINGTON (dpa-AFX) - Medtronic (MDT) announced the commercial launch in Europe of the MiniMed Go Smart MDI system with the Simplera sensor. The launch will be rolled out gradually across Europe... ► Artikel lesen | |
| HCA HEALTHCARE | 455,70 | +1,65 % | How Is HCA Healthcare's Stock Performance Compared to Other Healthcare Providers Stocks? | ||
| LANTHEUS | 64,58 | +1,86 % | Lantheus Holdings, Inc.: Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted... ► Artikel lesen | |
| ENVISTA | 24,200 | +0,83 % | Envista Holdings Corporation: Envista Reports Fourth Quarter 2025 Results | BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2025.
"With our... ► Artikel lesen | |
| CAREDX | 16,000 | +1,36 % | BTIG raises CareDx stock price target to $26 on strong Q4 results | ||
| GT BIOPHARMA | 0,460 | -2,02 % | GT Biopharma, Inc.: GT Biopharma Reports Full Year 2025 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Second Quarter Fiscal Year 2026 Results | Reports 14% Increase in ARR to $21.8 Million, Net Income of $547,000 and 36% Year-over-Year Growth in Adjusted EBITDA
HENDERSON, Nev., Feb. 12, 2026 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | The Versailles Economic Court has opted for the takeover bid within the context of a sales plan submitted by CARMAT SAS and approved the sale plan1 of CARMAT SA to CARMAT SAS
Regulatory News:
CARMAT... ► Artikel lesen | |
| CHEMOMETEC | 54,30 | -3,12 % | Chemometec A/S: Notification of managers' transactions | ||
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): QUARTERLY UPDATE AND CONTINUED SUSPENSION OF TRADING | ||
| POLAREAN IMAGING | 0,001 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 29.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 29.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 29.12.2025ISIN NameAU0000111395 PROSPECH... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,370 | -2,41 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| FRESENIUS | 50,78 | -1,05 % | Fresenius: Weiteres Wachstum in Sicht - Aktie bärenstark | Am kommenden Mittwoch (25. Februar) wird der Gesundheitskonzern Fresenius die Zahlen für das vergangene vierte Quartal respektive Gesamtjahr 2025 vorlegen. Der Markt rechnet sowohl umsatz- als auch... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,840 | +1,58 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| GENEDX | 74,20 | -6,98 % | These Analysts Slash Their Forecasts On GeneDx After Q4 Results |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-0,23 %) liegt der Kurs bei 8,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.